Scleroderma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The mainstay of treatment for scleroderma is medical therapy. Pharmacologic medical therapies for scleroderma include [[topical]] [[tacrolimus]] for [[morphea]], [[methotrexate]] for diffuse [[sclerosis]] of the [[skin]], [[minocycline]] for [[calcinosis cutis]], [[nifedipine]] for [[Raynaud's phenomenon]], [[captopril]] for scleroderma [[renal]] crisis, treatment of [[gastroesophageal reflux disease]] and [[pulmonary hypertension]]. Localized [[phototherapy]] with [[ultraviolet light]] is preferred for the treatment of [[morphea]]. | |||
[ | |||
==Medical Therapy== | ==Medical Therapy== | ||
Pharmacologic medical therapies for scleroderma include [[topical]] [[tacrolimus]] for [[morphea]], [[methotrexate]] for diffuse [[sclerosis]] of the [[skin]], [[minocycline]] for [[calcinosis cutis]], [[nifedipine]] for [[Raynaud's phenomenon]], [[captopril]] for scleroderma [[renal]] crisis, treatment of [[gastroesophageal reflux disease]] and [[pulmonary hypertension]]. | Pharmacologic medical therapies for scleroderma include [[topical]] [[tacrolimus]] for [[morphea]], [[methotrexate]] for diffuse [[sclerosis]] of the [[skin]], [[minocycline]] for [[calcinosis cutis]], [[nifedipine]] for [[Raynaud's phenomenon]], [[captopril]] for scleroderma [[renal]] crisis, treatment of [[gastroesophageal reflux disease]] and [[pulmonary hypertension]]. Localized [[phototherapy]] with [[ultraviolet light]] is preferred for the treatment of [[morphea]]. | ||
===Scleroderma=== | ===Scleroderma=== | ||
| Line 63: | Line 23: | ||
**** Preferred regimen (1): [[methotrexate]] 15 mg PO once weekly, maximum dose is 25 mg per week<ref name="pmid8624641">{{cite journal |vauthors=van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB |title=Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial |journal=Br. J. Rheumatol. |volume=35 |issue=4 |pages=364–72 |date=April 1996 |pmid=8624641 |doi= |url=}}</ref> | **** Preferred regimen (1): [[methotrexate]] 15 mg PO once weekly, maximum dose is 25 mg per week<ref name="pmid8624641">{{cite journal |vauthors=van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB |title=Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial |journal=Br. J. Rheumatol. |volume=35 |issue=4 |pages=364–72 |date=April 1996 |pmid=8624641 |doi= |url=}}</ref> | ||
**** Alternative regimen (1): [[mycophenolate]] mofetil 500 mg PO q12h for 7-14 days, then increase to maintenance dose of 500 mg to 1500 mg PO q12h as tolerated<ref name="pmid28188239">{{cite journal |vauthors=Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Jobanputra P, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP |title=Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS) |journal=Ann. Rheum. Dis. |volume=76 |issue=7 |pages=1207–1218 |date=July 2017 |pmid=28188239 |pmc=5530354 |doi=10.1136/annrheumdis-2016-210503 |url=}}</ref> | **** Alternative regimen (1): [[mycophenolate]] mofetil 500 mg PO q12h for 7-14 days, then increase to maintenance dose of 500 mg to 1500 mg PO q12h as tolerated<ref name="pmid28188239">{{cite journal |vauthors=Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Jobanputra P, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP |title=Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS) |journal=Ann. Rheum. Dis. |volume=76 |issue=7 |pages=1207–1218 |date=July 2017 |pmid=28188239 |pmc=5530354 |doi=10.1136/annrheumdis-2016-210503 |url=}}</ref> | ||
**** Alternative regimen (2): [[cyclophosphamide]] | **** Alternative regimen (2): [[cyclophosphamide]] ≤ 2 mg/kg PO daily<ref name="pmid16790698">{{cite journal |vauthors=Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M |title=Cyclophosphamide versus placebo in scleroderma lung disease |journal=N. Engl. J. Med. |volume=354 |issue=25 |pages=2655–66 |date=June 2006 |pmid=16790698 |doi=10.1056/NEJMoa055120 |url=}}</ref> | ||
** 1.3 '''Calcinosis''' | ** 1.3 '''Calcinosis''' | ||
*** 1.3.1 '''Adult''' | *** 1.3.1 '''Adult''' | ||
Revision as of 19:28, 11 May 2018
|
Scleroderma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Scleroderma medical therapy On the Web |
|
American Roentgen Ray Society Images of Scleroderma medical therapy |
|
Risk calculators and risk factors for Scleroderma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
The mainstay of treatment for scleroderma is medical therapy. Pharmacologic medical therapies for scleroderma include topical tacrolimus for morphea, methotrexate for diffuse sclerosis of the skin, minocycline for calcinosis cutis, nifedipine for Raynaud's phenomenon, captopril for scleroderma renal crisis, treatment of gastroesophageal reflux disease and pulmonary hypertension. Localized phototherapy with ultraviolet light is preferred for the treatment of morphea.
Medical Therapy
Pharmacologic medical therapies for scleroderma include topical tacrolimus for morphea, methotrexate for diffuse sclerosis of the skin, minocycline for calcinosis cutis, nifedipine for Raynaud's phenomenon, captopril for scleroderma renal crisis, treatment of gastroesophageal reflux disease and pulmonary hypertension. Localized phototherapy with ultraviolet light is preferred for the treatment of morphea.
Scleroderma
- 1 Treatment of skin manifestations
- 1.1 Limited cutaneous scleroderma-morphea
- 1.1.1 Adult
- Preferred regimen (1): localized phototherapy with ultraviolet light for 15 to 20 treatments[1]
- Preferred regimen (2): topical tacrolimus 0.1% ointment twice daily[2]
- Preferred regimen (3): methotrexate 15 mg PO once weekly, maximum dose is 25 mg per week[3]
- Alternative regimen (1): topical calcipotriene 0.005% ointment twice daily
- Alternative regimen (2): mycophenolate mofetil 500 mg PO q12h for 7-14 days, then increase to maintenance dose of 500 mg to 1500 mg PO q12h as tolerated[4]
- 1.1.1 Adult
- 1.2 Diffuse sclerosis of the skin
- 1.2.1 Adult
- Preferred regimen (1): methotrexate 15 mg PO once weekly, maximum dose is 25 mg per week[5]
- Alternative regimen (1): mycophenolate mofetil 500 mg PO q12h for 7-14 days, then increase to maintenance dose of 500 mg to 1500 mg PO q12h as tolerated[4]
- Alternative regimen (2): cyclophosphamide ≤ 2 mg/kg PO daily[6]
- 1.2.1 Adult
- 1.3 Calcinosis
- 1.3.1 Adult
- Preferred regimen (1): minocycline 50-100 mg PO q12h for 6-12 weeks[7]
- Alternative regimen (1): infliximab[8]
- Alternative regimen (2): rituximab[9]
- 1.3.1 Adult
- 1.4 Raynaud's phenomenon
- 1.4.1 Adult
- Oral regimen
- Preferred regimen (1): nifedipine 30-120 mg (extended release) PO once daily[10]
- Preferred regimen (2): amlodipine 5-20 mg PO once daily[11]
- Alternative regimen (1): sildenafil 20 mg PO once daily, then increase to a maximum dose of 20 mg PO q8h[12]
- Alternative regimen (2): losartan 50 mg PO once daily[13]
- Topical regimen
- Alternative regimen (3): Topical nitroglycerin applied to affected digits[14]
- Oral regimen
- 1.4.1 Adult
- 1.1 Limited cutaneous scleroderma-morphea
- 2 Treatment of gastrointestinal manifestations
- 2.1 Gastroesophageal reflux symptoms
- To review the treatment for gastroesophageal reflux symptoms click here.
- 3 Treatment of pulmonary manifestations
- 3.1 Pulmonary arterial hypertension
- To review the treatment for pulmonary arterial hypertension click here.
- 4 Treatment of renal manifestations
References
- ↑ Zwischenberger BA, Jacobe HT (November 2011). "A systematic review of morphea treatments and therapeutic algorithm". J. Am. Acad. Dermatol. 65 (5): 925–41. doi:10.1016/j.jaad.2010.09.006. PMID 21645943.
- ↑ Stefanaki C, Stefanaki K, Kontochristopoulos G, Antoniou C, Stratigos A, Nicolaidou E, Gregoriou S, Katsambas A (November 2008). "Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study". J. Dermatol. 35 (11): 712–8. doi:10.1111/j.1346-8138.2008.00552.x. PMID 19120765.
- ↑ Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE (June 2001). "A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma". Arthritis Rheum. 44 (6): 1351–8. doi:10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I. PMID 11407694.
- ↑ 4.0 4.1 Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirják L, Distler J, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Jobanputra P, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP (July 2017). "Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)". Ann. Rheum. Dis. 76 (7): 1207–1218. doi:10.1136/annrheumdis-2016-210503. PMC 5530354. PMID 28188239. Vancouver style error: initials (help)
- ↑ van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB (April 1996). "Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial". Br. J. Rheumatol. 35 (4): 364–72. PMID 8624641.
- ↑ Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M (June 2006). "Cyclophosphamide versus placebo in scleroderma lung disease". N. Engl. J. Med. 354 (25): 2655–66. doi:10.1056/NEJMoa055120. PMID 16790698.
- ↑ Robertson LP, Marshall RW, Hickling P (March 2003). "Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline". Ann. Rheum. Dis. 62 (3): 267–9. PMC 1754479. PMID 12594118.
- ↑ Tosounidou S, MacDonald H, Situnayake D (May 2014). "Successful treatment of calcinosis with infliximab in a patient with systemic sclerosis/myositis overlap syndrome". Rheumatology (Oxford). 53 (5): 960–1. doi:10.1093/rheumatology/ket365. PMID 24255162.
- ↑ de Paula DR, Klem FB, Lorencetti PG, Muller C, Azevedo VF (February 2013). "Rituximab-induced regression of CREST-related calcinosis". Clin. Rheumatol. 32 (2): 281–3. doi:10.1007/s10067-012-2124-z. PMID 23179007.
- ↑ Ennis H, Hughes M, Anderson ME, Wilkinson J, Herrick AL (February 2016). "Calcium channel blockers for primary Raynaud's phenomenon". Cochrane Database Syst Rev. 2: CD002069. doi:10.1002/14651858.CD002069.pub5. PMID 26914257.
- ↑ La Civita L, Pitaro N, Rossi M, Gambini I, Giuggioli D, Cini G, Ferri C (June 1993). "Amlodipine in the treatment of Raynaud's phenomenon". Br. J. Rheumatol. 32 (6): 524–5. PMID 8508292.
- ↑ Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL (October 2013). "Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials". Ann. Rheum. Dis. 72 (10): 1696–9. doi:10.1136/annrheumdis-2012-202836. PMID 23426043.
- ↑ Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM (December 1999). "Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial". Arthritis Rheum. 42 (12): 2646–55. doi:10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T. PMID 10616013.
- ↑ Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM (March 2009). "MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial". Arthritis Rheum. 60 (3): 870–7. doi:10.1002/art.24351. PMID 19248104.
- ↑ Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, Burns A, Denton CP (August 2007). "Scleroderma renal crisis: patient characteristics and long-term outcomes". QJM. 100 (8): 485–94. doi:10.1093/qjmed/hcm052. PMID 17601770.